Obstetrics. & Gynecology
Permanent URI for this communityhttps://repository.ui.edu.ng/handle/123456789/525
Browse
2 results
Search Results
Item The expression status of human epidermal growth factor receptor 2 in epithelial ovarian cancer in Ibadan, Nigeria(2016) Ajani, M. A.; Salami, A.; Awolude, O. A.; Oluwasola, A. O.; Akang, E. E. U.Background: It has been proposed that the overexpression of the human epidermal growth factor receptor 2 (HER2/neu protooncogene) could be a possible therapeutic target in epithelial ovarian cancer, as has been the case in breast carcinomas. However, there is lack of knowledge on the status of the gene in neoplasms which occur in black women. The objective of this study was to determine HER2/neu expression status in EOC in black women. Method: Ninety cases of EOC were evaluated for HER2/neu protein expression using immunohistochemistry. Results: HER-2/neu expression was observed in 33 of the 90 cases (37%), of which 15 EOC cases (17%) were weakly or moderately positive, and 18 (20%) strongly positive. A significant association was not found between HER-2/neu expression and age, International Federation of Gynecologists and Obstetrics (FIGO) stage, grading and histological subtypes (p-values of 0.463, 0.360, 0.975 and 0.168, respectively). However, there were more cases of advanced-stage disease (III/IV) with HER-2 expression than early-stage EOC (I/II). In this study, 21%, 36% and 42% of HER2/neu-positive tumours were grades 1, 2 and 3, respectively. A higher proportion of serous carcinomas (as opposed to mucinous carcinomas) was also observed to be ER2/neu positive. Conclusion: HER2/neu expression was observed to increase with advanced stages of cancer, and was more commonly seen in serous, rather than in mucinous, carcinomas.Item A review of vulvar and vaginal cancers in Ibadan, Nigeria(2013) Okolo, C. A.; Odubanjo, M. O.; Awolude, O. A.; Akang, E. E. U.The objectives of this study are to give an update on the previous studies on vulvar and vaginal cancers from the University College Hospital (UCH), Ibadan, Nigeria, to elucidate any changes in pattern, and to enumerate some of the factors affecting the management of these cancers at the UCH today. All the cases of cancer of the vulva and vagina seen at the UCH between January 1981 and December 2008 were reviewed and re-classified according to the World Health Organization (WHO) histological classification of 2004. The results are as follows: Vaginal and vulvar cancers were the 4th (1.4%) and 5th (1.2%) most common of the 5913 gynecological cancers seen. The mean age was 49.7 years. Squamous cell carcinoma (SCC) was the most common histological type. Notably, vulvar cancer is more common than vaginal cancer in the US and the UK and this opposes our findings. We studied time periods before and after the year 2000, and found vaginal cancer to be more common before and vulvar cancer after the year 2000. We suggest that this may be related to the introduction of the FIGO guidelines in 2000. We conclude that it is important to strictly adhere to the FIGO guidelines in determining the primary site of origin of these cancers in patients with advanced local disease as this distinction has implications for clinical management. The objectives of this study are to give an update on the previous studies on vulvar and vaginal cancers from the University College Hospital (UCH), Ibadan, Nigeria, to elucidate any changes in pattern, and to enumerate some of the factors affecting the management of these cancers at the UCH today. All the cases of cancer of the vulva and vagina seen at the UCH between January 1981 and December 2008 were reviewed and re-classified according to the World Health Organization (WHO) histological classification of 2004. The results are as follows: Vaginal and vulvar cancers were the 4th (1.4%) and 5th (1.2%) most common of the 5913 gynecological cancers seen. The mean age was 49.7 years. Squamous cell carcinoma (SCC) was the most common histological type. Notably, vulvar cancer is more common than vaginal cancer in the US and the UK and this opposes our findings. We studied time periods before and after the year 2000, and found vaginal cancer to be more common before and vulvar cancer after the year 2000. We suggest that this may be related to the introduction of the FIGO guidelines in 2000. We conclude that it is important to strictly adhere to the FIGO guidelines in determining the primary site of origin of these cancers in patients with advanced local disease as this distinction has implications for clinical management.